CBC Group redefines CNS care in China with UCB portfolio acquisition
Singapore-based CBC Group, Asia’s largest healthcare-dedicated asset management firm, has finalized its strategic acquisition of UCB’s mature neurology and allergy business in China. In partnership ... Read More
UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala
UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China for $680 million, marking a strategic shift ... Read More
Hasten Biopharmaceutical buys asset rights for 14 branded products from Celltrion
In a significant move, CBC Group, Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its portfolio company, Hasten Biopharmaceutical, has successfully acquired ... Read More